4 result(s) for "Anus"
-
1.
Tetanus Antitoxoid Antibody, IgG Assess immunity against tetanus by determining levels of circulating antibodies to tetanus toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders
Key Value PROCEDURE_ID 64755 PROCEDURE_NAME TETANUS ANTIBODY, IGG ORDER_DISPLAY_NAME Tetanus Antitoxoid Antibody, IgG PROCEDURE_MASTER_NUMBER LAB855 epic_synonyms TETANUS IMMUNE STATUS TETANUS TOXOID ANTIBODY ASSAY, SERUM pdm 5901246 cpt CPT Code: 86317 clinical_info Assess immunity against tetanus by determining levels of circulating antibodies to tetanus toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders methodology Enzyme Immunoassay (EIA) reference_values Reference Range
Nonprotective: <0.1 IU/mLperforming_location LabCorp of America compendium_synonyms volume 2862 results [{"base_name": "TETANTPSTIMM", "common_name": "TETANUS ANTIBODIES POST IMM", "external_name": "Tetanus Antibodies Post IMM", "component_name": "TETANUS ANTIBODIES POST IMM"}, {"base_name": "TETANTPDTE", "common_name": "TETANUS ANTIBODIES PRE DATE", "external_name": "Tetanus Antibodies Pre Date", "component_name": "TETANUS ANTIBODIES PRE DATE"}, {"base_name": "TETANTDT", "common_name": "TETANUS ANTIBODIES POST DATE", "external_name": "Tetanus Antibodies Post Date", "component_name": "TETANUS ANTIBODIES POST DATE"}, {"base_name": "TETANTPREIMM", "common_name": "TETANUS ANTIBODIES PRE IMM", "external_name": "Tetanus Antibodies Pre IMM", "component_name": "TETANUS ANTIBODIES PRE IMM"}, {"base_name": "TETANUSAB", "common_name": "TETANUS AB", "external_name": "Tetanus Antitoxoid IgG Ab", "component_name": "TETANUS ANTIBODIES IGG"}] name Tetanus Antitoxoid Antibody, IgG weight 3350 match_type order display name substring rank 11 -
2.
Diphtheria Antitoxoid Antibodies Assess immunity against diphtheria by determining levels of circulating antibodies to diphtheria toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders
Key Value PROCEDURE_ID 64692 PROCEDURE_NAME DIPHTHERIA / TETANUS ANTIBODY PANEL ORDER_DISPLAY_NAME Diphtheria Antitoxoid Antibodies PROCEDURE_MASTER_NUMBER LAB792 epic_synonyms DIPHTHERIA ANTIBODY pdm 5900545 cpt 86317 clinical_info Assess immunity against diphtheria by determining levels of circulating antibodies to diphtheria toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders methodology Enzyme Immunoassay (EIA) reference_values Nonprotective: <0.1 IU/mL
Protective: ≥0.1 IU/mLperforming_location LabCorp of America compendium_synonyms volume 1383 results [{"base_name": "DIPHTHERIAAB", "common_name": "DIPHTHERIA AB", "external_name": "Diphtheria Antitoxoid Ab", "component_name": "DIPHTHERIA ANTIBODY"}] name Diphtheria Antitoxoid Antibodies weight 700 match_type procedure name substring rank 12 -
3.
Quantitative JAK2 V617F Mutation Molecular Detection Myeloproliferative disorders (MPD) are believed to originate through transformation in hematopoietic stem cells (1). Polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF) are three main Ph-negative MPDs; these share many characteristics such as marrow hyper-cellularity, risk for thrombosis and hemorrhage and ...
Key Value PROCEDURE_ID 115143 PROCEDURE_NAME JAK2 V617F QUANTITATIVE ORDER_DISPLAY_NAME Quantitative JAK2 V617F Mutation Molecular Detection PROCEDURE_MASTER_NUMBER LAB11401 epic_synonyms 221 JAK-2 MUTATION CASE MPN JAK2, MUTANT JAK2 V617F ALLELIC BURDEN, BCR-ABL1 NEGATIVE TESTING pdm 5160105 cpt 81270 clinical_info Myeloproliferative disorders (MPD) are believed to originate through transformation in hematopoietic stem cells (1). Polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF) are three main Ph-negative MPDs; these share many characteristics such as marrow hyper-cellularity, risk for thrombosis and hemorrhage and transformation to leukemia.Recent studies on activated tyrosine kinases and signaling through Janus kinases have led to the identification of an acquired point mutation, G1849T in exon 14, in Janus kinase-2 (JAK2) gene in several patients with MPD. In fact, this mutation, V617F, in which phenylalanine is substituted for valine at position 617 has been reported in 95% of patients with PV, and in about 50 to 60% of patients with ET and IMF. This mutation is also reported in a few patients with other MPD conditions and Acute nonlymphocytic leukemia (ANLL), but not reported in patients with lymphoid malignancies, or Chronic myelogenous leukemia (CML). methodology Real-Time Polymerase Chain Reaction (PCR) reference_values An interpretative report will be provided.
performing_location Northwell Health Laboratories compendium_synonyms ["JAK2 V617F Quantitative"] volume results [{"base_name": null, "common_name": null, "external_name": null, "component_name": null}] name Quantitative JAK2 V617F Mutation Molecular Detection weight 600 match_type clinical info substring rank 15 -
4.
Lymphocyte Proliferation to Antigens Assessing T-cell function in patients on immunosuppressive therapy, including solid-organ transplant patients Evaluating patients suspected of having impairment in cellular immunity Evaluation of T-cell function in patients with primary immunodeficiencies, either cellular (DiGeorge syndrome, T-negative severe combined immunodeficiency: SCID, e...
Key Value PROCEDURE_ID 114352 PROCEDURE_NAME LYMPHOCYTE ANTIGENS ORDER_DISPLAY_NAME Lymphocyte Proliferation to Antigens PROCEDURE_MASTER_NUMBER LAB10939 epic_synonyms ANTIG/MITO pdm 5901650 cpt 86353 86353 (if appropriate) LOINC Code: 69042-0 clinical_info Assessing T-cell function in patients on immunosuppressive therapy, including solid-organ transplant patients Evaluating patients suspected of having impairment in cellular immunity Evaluation of T-cell function in patients with primary immunodeficiencies, either cellular (DiGeorge syndrome, T-negative severe combined immunodeficiency: SCID, etc) or combined T- and B-cell immunodeficiencies (T- and B-negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency, among others) where T-cell function may be impaired Evaluation of T-cell function in patients with secondary immunodeficiency, either disease related or iatrogenic Evaluation of recovery of T-cell function and competence following bone marrow transplantation or hematopoietic stem cell transplantation methodology Flow Cytometry reference_values Viability of lymphocytes at day 0: ≥75.0%
Maximum proliferation of Candida albicans as % CD45:
≥5.7%
Maximum proliferation of Candida albicans as % CD3:
≥3.0%
Maximum proliferation of tetanus toxoid as % CD45: ≥5.2%
Maximperforming_location Mayo Medical Laboratories NOTE: DO NOT DRAW FRIDAY, SATURDAY OR SUNDAY compendium_synonyms volume 184 results [{"base_name": "LYMPHAG", "common_name": "LYMPH ANTIGEN MITOGEN PROLIFE", "external_name": "Lymph Antigen/Mitogen Prolife", "component_name": "LYMPH ANTIGEN/MITOGEN PROLIFE"}] name Lymphocyte Proliferation to Antigens weight 400 match_type reference values substring rank 17